SMALL LYMPHOCYTIC LEUKEMIA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LEUKEMIA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LEUKEMIA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LEUKEMIA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack aims to wipe out blood cancer cells
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make …
Matched conditions: SMALL LYMPHOCYTIC LEUKEMIA (SLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New triple therapy aims to tame relapsed blood cancer
Disease control Recruiting nowThis study tests whether a combination of three drugs—pirtobrutinib, venetoclax, and obinutuzumab—can control relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who have had prior treatment will receive this time-limited therapy. The …
Matched conditions: SMALL LYMPHOCYTIC LEUKEMIA (SLL)
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC